A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

In this Monday edition of quantum computing news, we look at a new push by SEALSQ ($LAES) to build silicon-based quantum systems, Xanadu’s early ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Chinese AI company Deepseek has unveiled a new training method, Manifold-Constrained Hyper-Connections (mHC), which will make it possible to train large language models more efficiently and at lower ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

WIRED spoke with DeepMind’s Pushmeet Kohli about the recent past—and promising future—of the Nobel Prize-winning research ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

And, as we changed this means of interaction rather quickly, one way we did it has to do with games. Game engines are now AI ...